Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Revenue from antibody research support increased 24.2% year on year, and revenue from antibody and reagent sales increased 53.7%. Selling, general and administrative expenses decreased 1.5%. Non-operating income of ¥4.992 million, non-operating expenses of ¥2.329 million and an impairment loss of ¥516 thousand were recorded.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥35 million (YoY +49.9%) |
| Operating profit | ¥-204 million |
| Ordinary income | ¥-201 million |
| Profit attributable to owners of the parent | ¥-202 million |
| Net income per share | △¥11.85 |
| Equity ratio | End of the current fiscal period 68.5 / End of previous period 70.1 |
| Total assets | ¥1,665 million |
| Net assets | ¥1,222 million |
| Annual Dividend Forecast | 0.00 yen and sen → 0.00 yen and sen（0.0%） |
| Depreciation and amortization | ¥10 thousand |
| Impairment loss | ¥516 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥516 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 18,429,500 |
| Treasury Shares at Period-End | 90 |
| Factors Behind Changes in Business Performance | Revenue from antibody research support increased 24.2% year on year, and revenue from antibody and reagent sales increased 53.7%. Selling, general and administrative expenses decreased 1.5%. Non-operating income of ¥4.992 million, non-operating expenses of ¥2.329 million and an impairment loss of ¥516 thousand were recorded. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from antibody research support was ¥3.788 million, up 24.2% year on year, mainly from the provision of services and related activities. Revenue from antibody and reagent sales was ¥31.396 million, up 53.7%. Selling, general and administrative expenses were ¥236.262 million, down 1.5%, resulting in a narrower operating loss. The ordinary loss reflected non-operating expenses of ¥2.329 million and non-operating income of ¥4.992 million, while the net loss for the quarter included an impairment loss of ¥516 thousand and other items. The full-year forecast has not been provided because it is difficult to reasonably forecast the amount of upfront payments and other income, and their impact on revenue, arising from the out-licensing of PPMX-T002 and PPMX-T003.